此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项关于IBI3003在复发或难治性多发性骨髓瘤受试者中的研究

2026年9月22日 更新者:Fortvita Biologics (USA)Inc.

一项针对复发或难治性多发性骨髓瘤患者的IBI3003 I/II期、多中心、开放性研究

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

360

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Arizona
      • Scottsdale、Arizona、美国、85258
        • 主动,不招人
        • Honor Health
    • California
      • Duarte、California、美国、91010
      • Irvine、California、美国、92618
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 主动,不招人
        • Emory
    • New York
      • New York、New York、美国、10021
    • Texas
      • Houston、Texas、美国、77030

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

Participants in Parts 1 & 2 must satisfy all of the following criteria to be enrolled in the study:

  1. Age ≥18 years.

  2. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.

    Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and any one or more of the following myelomadefining events:

    • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or corrected serum calcium >2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
    • Any one or more of the following biomarkers of malignancy:

    Clonal bone marrow plasma cell percentage ≥60% Involved: uninvolved serum free light chain ratio ≥100 (involved FLC level must be

    ≥100 mg/L) >1 focal lesions on MRI studies (at least 5 mm in size)

  3. Relapsed or refractory measurable multiple myeloma (R/R MM) following prior treatment with ≥3 lines of systemic anti-myeloma therapy that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy, and with limited or no therapeutic options that are likely to offer a favorable risk/benefit profile; participants must be relapsed or refractory to their last anti-myeloma regimen.

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

  5. At least one of the following measurable disease indicators:

    • Serum M-protein ≥5 g/L (for IgA and IgD subtypes, quantitative immunoglobin measurements could be used as substitutions for M-protein)
    • Urine M-protein ≥200 mg/24h
    • Serum free light chain (FLC) test: affected FLC level ≥100 mg/L and abnormal serum FLC ratio (<0.26 or >1.65)
  6. Adequate hematologic, hepatic, renal and cardiac function:

    • Blood count: absolute neutrophil count ≥1.0×10^9/L, hemoglobin ≥70 g/L, and platelet count ≥50×10^9/L (values must be achieved without growth factors or blood transfusions within 7 days prior to first dose)
    • Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤2.5× upper limit of normal (ULN) and total bilirubin (TBIL) ≤1.5×ULN
    • Renal function: calculated creatinine ≥30 mL/min by the Cockcroft-Gault Equation
    • Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%
  7. Life expectancy ≥3 months.

  8. Women of childbearing potential and fertile men who are sexually active must agree to use a highly effective method of contraception (<1% / year failure rate) during the study and for 90 days after the last dose level of study drug. Contraception must be consistent with local regulations or standards regarding the use of birth control methods by participants participating in clinical trials. Women and men must agree not to donate or bank eggs (ova, oocytes) or sperm, respectively, during the study and for 90 days after the last dose level of study drug.

  9. Participants with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.

  10. Willing and able to adhere to the complete schedule of assessments and all prohibitions and restrictions specified in this protocol

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.

  2. Active amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or solitary plasmacytoma, or smoldering multiple myeloma (MM) as defined by the IMWG criteria.

  3. Spinal cord compression that results in limited self-care at present or within 6 months prior to informed consent, or that is expected to cause such limitations during Study participation.

  4. History of primary immunodeficiency.

  5. Current or previous other malignancy within 3 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.

  6. Allogeneic hematopoietic stem cell transplantation within the last 6 months, or autologous stem cell transplantation within the last 3 months prior to the first administration of the study drug.

  7. History of organ transplantation.

  8. Active graft-versus-host disease.

  9. Thromboembolism or cerebrovascular events (e.g., myocardial infarction, unstable angina, transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with complications of central venous access], or pulmonary embolism) within 6 months prior to the first dose of study drug.

  10. Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.

  11. Known allergies, hypersensitivity, or intolerance to IBI3003 or its excipients (refer to Investigator's Brochure).

  12. Prior toxicities that have not resolved to ≤Grade 1 prior to study treatment administration except for stable chronic toxicities (≤Grade 2) not expected to resolve (e.g., stable Grade 2 peripheral neurotoxicity)

  13. Prior antitumor therapy as follows, prior to the first dose of study drug:

    • Gene modified adoptive cell therapy (e.g., chimeric antigen receptor modified T cells, natural killer cells) within 8 weeks.
    • Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer.
    • Antibody treatment (e.g., monoclonal antibody, bispecific antibody) for multiple myeloma within 21 days.
    • Cytotoxic therapy (including antibody-drug conjugates) within 14 days.
    • Proteasome inhibitor therapy within 14 days Immunomodulatory agent therapy within 7 days.
    • Radiotherapy within 21 days. However, if the radiation field covered ≤5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy.
    • Cancer vaccine received within 3 months.
  14. Use of immunosuppressive therapy within 28 days of the start date of study treatment.

    Immunosuppressive therapy includes, but is not limited to, cyclosporine A, tacrolimus, and mycophenolate mofetil, but does not include corticosteroids given as part of an antimyeloma regimen. Participants receiving corticosteroids must be at a dose level ≤10 mg/day of prednisone equivalent for at least 7 days prior to the start of study treatment administration.

  15. Live or live attenuated vaccine administered within 4 weeks prior to start of study treatment, or anticipated need for live or live attenuated vaccine during the study.

  16. Uncontrolled diseases, including:

    • Uncontrolled infection or infection requiring systemic antibiotics, antivirals or antifungals within one week prior to first administration of the study drug;
    • Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
    • For participants in mainland China, acute or chronic active hepatitis B (HBsAg positive and/or HBcAb positive with HBV DNA titer ≥104 copies/mL or ≥2000 IU/mL) or C (HCV Ab positive with HCV RNA>103 copies/mL). For participants outside of mainland China, active, latent or incompletely treated infection with HBV or HCV;
    • Failed to complete anti-tuberculosis therapy at any point prior to C1D1; active tuberculosis infection, or still on anti-tuberculosis therapy;
    • Active syphilis infection requiring treatment;
    • Symptomatic congestive heart failure Grade II-IV (New York Heart Association [NYHA]), symptomatic or uncontrolled arrhythmias, QTc interval (calculate using the Fridericia formula) >480 ms, or personal or family history of congenital long/short QT syndrome;
    • Uncontrollable hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg);
    • Active autoimmune diseases, including but not limited to inflammatory bowel disease, autoimmune hepatitis, demyelinating lesions, extensive dermatitis, immunerelated interstitial pneumonia, or Grave's disease requiring antithyroid medication control (vitiligo, or hypothyroidism requiring hormone replacement therapy, type I diabetes requiring only insulin replacement therapy and no other systemic therapy in the past 2 years are eligible); Presence of clinically uncontrolled pleural/peritoneal effusions (participants who do not require regular drainage or who do not demonstrate significant re-accumulation of effusion for at least 72 hours after the most recent drainage can enroll).
  17. Major surgery within 2 weeks prior to the first dose of study treatment, not fully recovered from any prior surgery, or has non-minor surgery anticipated during the time the participant is expected to receive study drug or within 2 weeks after the last dose of study drug administration.

  18. Participating in any other interventional clinical research except an observational (noninterventional) study or the survival follow-up phase of an interventional study.

  19. Currently pregnant or breastfeeding.

  20. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

  21. Inability to comprehend or unwilling to sign the ICF

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:IBI3003

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Adverse events (AEs)
大体时间:Up to 30 days post last dose

Number of patients who Experienced related AEs from the first dose until 30 days after the last dose

Up to 30 days post last dose
Dose limiting toxicities (DLTs)
大体时间:Up to 28 days post first dose

To evaluate the safety and tolerability of IBI3003

Up to 28 days post first dose
ORR
大体时间:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003
大体时间:up to 24 months

To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003

up to 24 months

次要结果测量

结果测量
措施说明
大体时间
Incidence and characterization of anti-drug antibody (ADA).
大体时间:up to 24 months

To evaluate the immunogenicity of IBI3003

up to 24 months
Preliminary efficacy including objective response rate (ORR)
大体时间:up to 24 months

objective response rate. To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To evaluate minimal residual disease (MRD) negativity rates. MRD negativity rate.
大体时间:up to 24 months

To evaluate minimal residual disease (MRD) negativity rates.

up to 24 months
efficacy estimates sCRR
大体时间:up to 24 months

stringent complete response rate. To evaluate other efficacy estimates of IBI3003 in the participant population.

up to 24 months
Incidence of TEAEs
大体时间:up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
half-life (T1/2)
大体时间:up to 24 months

To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
time to maximum concentration (Tmax)
大体时间:up to 24 months

time to peak concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
maximum concentration (Cmax)
大体时间:peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months

peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.
area under the curve (AUC)
大体时间:up to 24 months

area under the curve. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
complete response rate (CRR)
大体时间:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
very good partial response rate (VGPRR)
大体时间:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
duration of response (DoR)
大体时间:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
disease control rate (DCR)
大体时间:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
time to response (TTR)
大体时间:To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.
progression free survival (PFS).
大体时间:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
SAEs
大体时间:up to 24 months

serious adverse events (SAEs) Adverse events will be assessed by investigator(s) To evaluate the safety of IBI3003 in the participant population.

up to 24 months
changes in laboratory parameters
大体时间:up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
physical examination findings
大体时间:up to 24 months

A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.To evaluate the safety of IBI3003 in the participant population.

up to 24 months
vital signs
大体时间:up to 24 months

Collection of vital signs will include temperature in ℃, measurement tool is physiological parameter.To evaluate the safety of IBI3003 in the participant population.

up to 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月30日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2026年1月8日

首先提交符合 QC 标准的

2026年1月12日

首次发布 (实际的)

2026年1月13日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅